Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients

International Journal of Antimicrobial Agents

Volumn 34, Issue 5, 2009, Pages 429-433

  Shea, Katherine M ^a   Cheatham, S Christian ^b   Wack, Matthew F ^c   Smith, David W ^a   Sowinski, Kevin M ^d   Kays, Michael B ^d  

^a METHODIST HOSPITAL   (United States)

^b St Francis Hospital   (United States)

^c Infectious Diseases of Indiana   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Monte Carlo; Pharmacodynamics; Pharmacokinetics; Piperacillin; Tazobactam

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ACINETOBACTER; ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CITROBACTER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; SERUM; UNITED STATES;

EID: 70249113663     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.07.004     Document Type: Article

References (35)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
2. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44 (2007) 79-86
3. Lodise T.P., Lomaestro B.M., and Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 26 (2006) 1320-1332
4. Mattoes H.M., Kuti J.L., Drusano G.L., and Nicolau D.P. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 26 (2004) 1187-1198
5. Kuti J.L., Dandekar P.K., Nightingale C.H., and Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43 (2003) 1116-1123
6. Kim A., Sutherland C.A., Kuti J.L., and Nicolau D.P. Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?. Pharmacotherapy 27 (2007) 1490-1497
7. Gin A., Dilay L., Karlowsky J.A., Walkty A., Rubinstein E., and Zhanel G.G. Piperacillin/tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5 (2007) 365-383
8. Snydman D.R., Jacobus N.V., and McDermott L.A. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother 52 (2008) 4492-4496
9. ® (piperacillin/tazobactam) package insert. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2007.
10. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
11. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
12. Kim M.K., Capitano B., Mattoes H.M., Xuan D., Quintiliani R., Nightingale C.H., et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens of piperacillin-tazobactam. Pharmacotherapy 22 (2002) 569-577
13. Cheatham S.C., Kays M.B., Smith D.W., Wack M.F., and Sowinski K.M. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients. Pharmacotherapy 28 (2008) 691-698
14. Barbhaiya R.H., Forgue S.T., Gleason C.R., Knupp C.A., Pittman K.A., Weidler D.J., et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 36 (1992) 552-557
15. Benet L.Z., and Galeazzi R.L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68 (1979) 1071-1072
16. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother 17 (2005) 459-469
17. Rhomberg P.R., and Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 57 (2007) 207-215
18. Rhomberg P.R., Deshpande L.M., Kirby J.T., and Jones R.N. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis 59 (2007) 425-432
19. Jones R.N., Kirby J.T., and Rhomberg P.R. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 61 (2008) 203-213
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
21. DeRyke C.A., Kuti J.L., and Nicolau D.P. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 27 (2007) 333-342
22. Lodise T.P., Lomaestro B., Rodvold K.A., Danziger L.H., and Drusano G.L. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 48 (2004) 4718-4724
23. Lodise T.P., Lomaestro B., and Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44 (2007) 357-363
24. Johnson C.A., Halstenson C.E., Kelloway J.S., Shapiro B.E., Zimmerman S.W., Tonelli A., et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 51 (1992) 32-41
25. Jhee S.S., Kern J.W., Burm J.P., Yellin A.E., and Gill M.A. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Pharmacotherapy 15 (1995) 472-478
26. Bourget P., Lesne-Hulin A., Le Reveille R., Le Bever H., and Carsin H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40 (1996) 139-145
27. Occhipinti D.J., Pendland S.L., Schoonover L.L., Rypins E.B., Danziger L.H., and Rodvold K.A. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 41 (1997) 2511-2517
28. Burgess D.S., and Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 24 (2002) 1090-1104
29. Li C., Kuti J.L., Nightingale C.H., Mansfield D.L., Dana A., and Nicolau D.P. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56 (2005) 388-395
30. Buck C., Bertram N., Ackermann T., Sauerbruch T., Derendorf H., and Paar W.D. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25 (2005) 62-67
31. Roberts J.A., Roberts M.S., Robertson T.A., Dalley A.J., and Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration. Crit Care Med 37 (2009) 926-933
32. Tam V.H., Gamez E.A., Weston J.S., Gerard L.N., LaRocco M.T., Caeiro J.P., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 46 (2008) 862-867
33. DeRyke C.A., Kuti J.L., and Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58 (2007) 337-344
34. Frei C.R., Wiederhold N.P., and Burgess D.S. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61 (2008) 621-628
35. Crandon J.L., Kuti J.L., Jones R.N., and Nicolau D.P. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance. Ann Pharmacother 43 (2009) 220-227